William Cook
Cardiovascular Disease · Wauchula, FLNPI 1699700930
Payments from drug & device makers
Across 91 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$268
- Abbott$229
- AstraZeneca$148
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$95
- Amgen$90
- Novartis$88
- plus $623 from 16 others
What the payments were for
- Food & beverage$1,52299%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $268 |
| Abbott | 11 | $229 |
| AstraZeneca(2 entities) | 10 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $95 |
| Amgen | 4 | $90 |
| Novartis | 6 | $88 |
| Boston Scientific | 5 | $87 |
| Biotronik Inc. | 5 | $84 |
| Merck | 5 | $79 |
| Cvrx, Inc. | 4 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Pfizer | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Philips North America LLC | 1 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $33 |
| Boehringer Ingelheim | 2 | $32 |
| Atricure, Inc. | 1 | $31 |
| Medtronic | 2 | $25 |
| Astellas Pharma US Inc | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $5 |
How this compares
$1,540 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $22,426 |
| Amlodipine Besylate | 53 | $340 |
| ClopidogrelClopidogrel Bisulfate | 34 | $317 |
| Losartan Potassium | 18 | $193 |
| Atorvastatin Calcium | 23 | $154 |
| Lisinopril | 20 | $124 |
| Carvedilol | 11 | $105 |
| Metoprolol Tartrate | 14 | $84 |
| Furosemide | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $22,42620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wauchula
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.